- Home
- CLLS vs BDSX Comparison
CLLS vs BDSX Comparison
Compare CLLS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- BDSX
- Stock Information
- Founded
- CLLS 1999
- BDSX 2005
- Country
- CLLS France
- BDSX United States
- Employees
- CLLS N/A
- BDSX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- BDSX Precision Instruments
- Sector
- CLLS Health Care
- BDSX Health Care
- Exchange
- CLLS Nasdaq
- BDSX Nasdaq
- Market Cap
- CLLS 240.2M
- BDSX 245.3M
- IPO Year
- CLLS 2007
- BDSX 2020
- Fundamental
- Price
- CLLS $2.01
- BDSX $1.69
- Analyst Decision
- CLLS Buy
- BDSX Strong Buy
- Analyst Count
- CLLS 2
- BDSX 4
- Target Price
- CLLS $8.00
- BDSX $3.08
- AVG Volume (30 Days)
- CLLS 22.9K
- BDSX 247.5K
- Earning Date
- CLLS 11-04-2024
- BDSX 11-05-2024
- Dividend Yield
- CLLS N/A
- BDSX N/A
- EPS Growth
- CLLS N/A
- BDSX N/A
- EPS
- CLLS N/A
- BDSX N/A
- Revenue
- CLLS $19,635,000.00
- BDSX $60,902,000.00
- Revenue This Year
- CLLS $271.02
- BDSX $48.06
- Revenue Next Year
- CLLS $33.48
- BDSX $29.97
- P/E Ratio
- CLLS N/A
- BDSX N/A
- Revenue Growth
- CLLS N/A
- BDSX 46.25
- 52 Week Low
- CLLS $0.96
- BDSX $1.15
- 52 Week High
- CLLS $3.77
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- CLLS 41.74
- BDSX 46.06
- Support Level
- CLLS $1.95
- BDSX $1.62
- Resistance Level
- CLLS $2.06
- BDSX $1.71
- Average True Range (ATR)
- CLLS 0.10
- BDSX 0.06
- MACD
- CLLS -0.01
- BDSX -0.00
- Stochastic Oscillator
- CLLS 33.33
- BDSX 47.62
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.